Literature DB >> 12655085

Galactose is needed only for expression of co-receptors used by Theiler's murine encephalomyelitis virus as the virus does not directly bind galactose or use the UDP-galactose transporter as a receptor.

Honey V Reddi1,2,3, Patricia Kallio2,3, Howard L Lipton1,3,2,4.   

Abstract

Theiler's murine encephalomyelitis virus (TMEV) infects most mammalian cells, but a TMEV receptor has not been identified. Studies have demonstrated that the UDP-galactose transporter (UGT) is critical for TMEV attachment and entry into mammalian cells (Hertzler et al., Virology 286, 336-344, 2001). It was suggested that UGT might function as a TMEV receptor. We have demonstrated that polyclonal rabbit antibodies to human UGT that cross-react with hamster UGT do not block binding to or infection of mammalian cells by either high- or low-neurovirulence TMEV. In addition, incubation of virus with galactose, or blocking galactose on the cell surface with lectins, does not inhibit TMEV binding or infection. Thus, TMEV needs UGT for its transporter activity and galactose for assembly of its co-receptors (attachment factors) but does not bind directly to galactose. Excluding direct involvement of UGT and galactose in TMEV binding and entry provides further insight into how TMEV interacts with the host cell and should facilitate ongoing studies to identify a TMEV receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655085     DOI: 10.1099/vir.0.18746-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

Review 1.  Differential usage of carbohydrate co-receptors influences cellular tropism of Theiler's murine encephalomyelitis virus infection of the central nervous system.

Authors:  Howard L Lipton; A S Manoj Kumar; Shannon Hertzler; Honey V Reddi
Journal:  Glycoconj J       Date:  2006-02       Impact factor: 2.916

2.  Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy.

Authors:  Kevin D Pavelko; Megan A Girtman; Yoshihiro Mitsunaga; Yanice V Mendez-Fernandez; Michael P Bell; Michael J Hansen; Kathleen S Allen; Moses Rodriguez; Larry R Pease
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.